Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 18/20 | 0.64 |
| ▸ | DRD3 | P35462 | 13/20 | 0.64 |
| ▸ | DRD4 | P21917 | 9/20 | 0.64 |
| ▸ | HTR1A | P08908 | 3/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5502557 | 0.90 | DRD3 (0.62) | DRD2DRD3DRD4HTR1AHTR2C | |
| SCHEMBL5510364 | 0.89 | DRD2 (0.58) | DRD2DRD3DRD4HTR1AHTR2C | |
| SCHEMBL5505000 | 0.85 | DRD2 (0.64) | DRD2DRD3DRD4HTR1AHTR2C | |
| SCHEMBL5510402 | 0.84 | DRD2 (0.66) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL5262985 | 0.82 | DRD3 (0.51) | DRD2DRD3DRD4HTR1AHTR2C | |
| SCHEMBL5501793 | 0.82 | DRD2 (0.66) | DRD2DRD3DRD4HTR1AHTR2C | |
| SCHEMBL5503595 | 0.82 | DRD2 (0.53) | DRD2DRD3DRD4HTR1AHTR2C | |
| SCHEMBL4916604 | 0.76 | DRD3 (0.47) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL5507888 | 0.76 | DRD2 (0.62) | DRD2DRD3DRD4HTR1AHTR2C | |
| SCHEMBL4911937 | 0.75 | DRD3 (0.47) | DRD2DRD3DRD4HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1519726-B1 | UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-02-21 | — | — | EP | claimed |
| EP-1749529-A1 | Utilisation of heteroarene carboxamide as dopamine-D3 ligands for the treatment of CNS diseases | SCHWARZ PHARMA AG (DE) | 2007-02-07 | — | — | EP | claimed |
| US-20050197343-A1 | Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases | SCHWARZ PHARMA AG (DE) | 2005-09-08 | — | — | US | claimed |
| EP-1519726-B1 | UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-02-21 | — | — | EP | disclosed |
| EP-1749529-A1 | Utilisation of heteroarene carboxamide as dopamine-D3 ligands for the treatment of CNS diseases | SCHWARZ PHARMA AG (DE) | 2007-02-07 | — | — | EP | disclosed |
| US-20050197343-A1 | Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases | SCHWARZ PHARMA AG (DE) | 2005-09-08 | — | — | US | disclosed |
| EP-1519726-A1 | UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES | SCHWARZ PHARMA AG (DE) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004004729-A1 | UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES | SCHWARZ PHARMA AG (DE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197343-A1 | Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases | SLC6A3, DRD2, ADH1A | DRD2 2/4885DRD3 9/4885DRD4 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.